دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Effect of Personalized Accelerated Pacing on Quality of Life, Physical Activity, and Atrial Fibrillation in Patients With Preclinical and Overt Heart Failure With Preserved Ejection FractionThe myPACE Randomized Clinical Trial
Margaret Infeld, MD, MS1; Kramer Wahlberg, MD1; Jillian Cicero, BS1; Timothy B. Plante, MD, MHS1; Sean Meagher, MD2; Alexandra Novelli, BS1; Nicole Habel, MD, PhD1; Anand Muthu Krishnan, MD1; Daniel N. Silverman, MD3; Martin M. LeWinter, MD1; Daniel L. Lustgarten, MD, PhD1; Markus Meyer, MD, PhD1,4
doi : 10.1001/jamacardio.2022.5320
March 2023, Vol 8, No. 3, Pages 212-302
Importance Patients with heart failure with preserved ejection fraction (HFpEF) with a pacemaker may benefit from a higher, more physiologic backup heart rate than the nominal 60 beats per minute (bpm) setting.
Association of Long-term Change in N-Terminal Pro–B-Type Natriuretic Peptide With Incident Heart Failure and Death
Xiaoming Jia, MD1; Mahmoud Al Rifai, MD, MPH1,2; Ron Hoogeveen, PhD3; Justin B. Echouffo-Tcheugui, MD, PhD4; Amil M. Shah, MD, MPH5; Chiadi E. Ndumele, MD, MHS6; Salim S. Virani, MD, PhD1,3,7; Biykem Bozkurt, MD, PhD1,7; Elizabeth Selvin, PhD, MPH8; Christie M. Ballantyne, MD1,3; Vijay Nambi, MD, PhD1,3,7
Association of Rurality With Risk of Heart Failure
Sarah E. Turecamo, BA1; Meng Xu, MS2,3; Debra Dixon, MD, MS2,4; Tiffany M. Powell-Wiley, MD, MPH5,6; Michael T. Mumma, MS7; Jungnam Joo, PhD8; Deepak K. Gupta, MD, MSCI2,4; Loren Lipworth, ScD2,9,10; Véronique L. Roger, MD, MPH1
doi : 10.1001/jamacardio.2022.5211
Importance Rural populations experience an increased burden of heart failure (HF) mortality compared with urban populations. Whether HF incidence is greater among rural individuals is less known. Additionally, the intersection between racial and rural health inequities is understudied.
Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen ConsumptionA Secondary Analysis of the EXPLORER-HCM Randomized Trial
Matthew T. Wheeler, MD, PhD1; Iacopo Olivotto, MD2,3; Perry M. Elliott, MD4; Sara Saberi, MD5; Anjali T. Owens, MD6; Mathew S. Maurer, MD7; Ahmad Masri, MD8; Amy J. Sehnert, MD9; Jay M. Edelberg, MD, PhD9; Yu-Mao Chen, MSc10; Victoria Florea, MD9; Rajeev Malhotra, MD11; Andrew Wang, MD12; Artur Oręziak, MD13; Jonathan Myers, PhD14,15
doi : 10.1001/jamacardio.2022.5099
Importance Mavacamten, a cardiac myosin inhibitor, improved peak oxygen uptake (pVO2) in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in the EXPLORER-HCM study. However, the full extent of mavacamten’s effects on exercise performance remains unclear.
Effectiveness of Simulation-Based Training on Transesophageal Echocardiography LearningThe SIMULATOR Randomized Clinical Trial
Théo Pezel, MD1,2,3; Julien Dreyfus, MD4; Basile Mouhat, MD5; Clémence Thébaut, MD6; Etienne Audureau, MD, PhD7; Anne Bernard, MD, PhD8,9,10; Yoan Lavie Badie, MD11; Yohann Bohbot, MD, PhD12,13,14; Damien Fard, MD15; Lee S. Nguyen, MD, PhD16; Cécile Monteil, MD2; Loïc Bière, MD, PhD17; Florent Le Ven, MD, PhD18,19; Marjorie Canu, MD20; Sophie Ribeyrolles, MD21; Baptiste Mion, MD22; Baptiste Bazire, MD23; Charles Fauvel, MD24,25; Jennifer Cautela, MD, PhD26; Théo Cambet, MD27; Thierry Le Tourneau, MD, PhD28; Erwan Donal, MD, PhD29; Stéphane Lafitte, MD, PhD30; Julien Magne, PhD31; Nicolas Mansencal, MD, PhD32,33; Augustin Coisne, MD, PhD34,35,36; for the SIMULATOR investigators
doi : 10.1001/jamacardio.2022.5016
Importance Evidence is scarce on the effectiveness of simulation-based training in transesophageal echocardiography (TEE).
Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease
Jacqueline S. Dron, PhD1,2; Aniruddh P. Patel, MD1,2,3,4; Yiyi Zhang, PhD5; Sean J. Jurgens, MD2,6; Dimitri J. Maamari, MD1,2,3; Minxian Wang, PhD7,8; Eric Boerwinkle, PhD9; Alanna C. Morrison, PhD9; Paul S. de Vries, PhD9; Myriam Fornage, PhD9,10; Lifang Hou, MD, PhD11; Donald M. Lloyd-Jones, MD, ScM11; Bruce M. Psaty, MD, PhD12,13,14; Russell P. Tracy, PhD15,16; Joshua C. Bis, PhD12; Ramachandran S. Vasan, MD17,18,19; Daniel Levy, MD19,20; Nancy Heard-Costa, PhD19,21; Stephen S. Rich, PhD22; Xiuqing Guo, PhD23; Kent D. Taylor, PhD23; Richard A. Gibbs, PhD24; Jerome I. Rotter, MD23; Cristen J. Willer, PhD25; Elizabeth C. Oelsner, MD5; Andrew E. Moran, MD, MPH5; Gina M. Peloso, PhD26; Pradeep Natarajan, MD, MMSc2,3,4; Amit V. Khera, MD, MSc1,2,3,27
doi : 10.1001/jamacardio.2022.5271
Importance Protein-truncating variants (PTVs) in apolipoprotein B (APOB) and proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with significantly lower low-density lipoprotein (LDL) cholesterol concentrations. The association of these PTVs with coronary heart disease (CHD) warrants further characterization in large, multiracial prospective cohort studies.
Association of Plasma High-Density Lipoprotein Cholesterol Level With Risk of Fractures in Healthy Older Adults
Sultana Monira Hussain, MBBS, PhD1,2; Peter R. Ebeling, MD3; Anna L. Barker, PhD1,4; Lawrence J. Beilin, MD5; Andrew M. Tonkin, MD1; John J. McNeil, MBBS, PhD1
doi : 10.1001/jamacardio.2022.5124
Importance Increased levels of high-density lipoprotein cholesterol (HDL-C) have been associated with osteoporosis. Preclinical studies have reported that HDL-C reduces bone mineral density by reducing osteoblast number and function. However, the clinical significance of these findings is unclear.
Association of Tafamidis With Health Status in Patients With ATTR Cardiac AmyloidosisA Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial
Brett W. Sperry, MD1,2; Mazen Hanna, MD3; Mathew S. Maurer, MD4; Jose Nativi-Nicolau, MD5; Lysbeth Floden, PhD6; Michelle Stewart, PhD7; Kathleen W. Wyrwich, PhD7; Alexandra I. Barsdorf, PhD6; Heli Kapadia, MPH6; John A. Spertus, MD, MPH1,2
doi : 10.1001/jamacardio.2022.5251
Importance Tafamidis reduced all-cause mortality and cardiovascular-related hospitalizations and minimized patient-reported health status deterioration at 30 months in patients with transthyretin (ATTR) amyloidosis.
Estimation of Out-of-Pocket Costs for Guideline-Directed Medical Therapy for Heart Failure Under Medicare Part D and the Inflation Reduction Act
Micah Johnson, MD1; Rahul K. Nayak, MD2; Lauren Gilstrap, MD, MPH3; Stacie B. Dusetzina, PhD4
Jump-starting the Journey to Transesophageal Echocardiogram Mastery
Michael Spooner, MD, MBA1; Kathryn Berlacher, MD, MS2
Higher High-Density Lipoprotein Cholesterol—Good Omen, Bad Omen, or Not an Omen at All
John Wilkins, MD1,2; Anand Rohatgi, MD, MSCS3
Management Challenges in Patients Younger Than 65 Years With Severe Aortic Valve DiseaseA Review
Jayson R. Baman, MD1; Ankit N. Medhekar, MD2; S. Chris Malaisrie, MD3; Patrick McCarthy, MD3; Charles J. Davidson, MD1; Robert O. Bonow, MD, MS1,4
doi : 10.1001/jamacardio.2022.4770
Importance The management of aortic valve disease, including aortic stenosis and aortic regurgitation (AR), in younger adult patients (age <65 years) is complex, and the optimal strategy is often unclear, contingent on multiple anatomic and holistic factors.
Quantifying and Interpreting the Prediction Accuracy of Models for the Time of a Cardiovascular Event—Moving Beyond C StatisticA Review
Xuan Wang, PhD1; Brian Lee Claggett, PhD2; Lu Tian, ScD3; Marcus VinÃcius BolÃvar Malachias, MD, PhD4; Marc A. Pfeffer, MD, PhD2; Lee-Jen Wei, PhD1
doi : 10.1001/jamacardio.2022.5279
Importance For personalized or stratified medicine, it is critical to establish a reliable and efficient prediction model for a clinical outcome of interest. The goal is to develop a parsimonious model with fewer predictors for broad future application without compromising predictability.
One Beat Is All It Takes—Wide Complex Tachycardia in a Middle-aged Man
Samuel Sauerwein, MD1; Jenna Spears, MB, BCh, BAO1; Gan-Xin Yan, MD, PhD1,2
A Man in His 30s With Splenic Infarct and Stroke
Harry Wang, MD1; Nilesh Rao, BS2; Karl Schwarz, MD1
Defining Rural in Rural-Urban Differences in Myocardial Infarction Management
Scott A. Cohen, MPH1,2
Defining Rural in Rural-Urban Differences in Myocardial Infarction Management—Reply
Khaled M. Ziada, MD1; Dustin Hillerson, MD2
